Last updated July 12, 2026
Key finding
Semaglutide increased time in the target range by a mean 4.8 percentage points (P = 0.006).
This study evaluated the effects of semaglutide on glycemic control in adults with Type 1 diabetes using automated insulin delivery. Semaglutide improved the percentage of time spent in the target glucose range significantly.
Quick read
The essential study design details in one scan.
EvidenceScore™
Moderate
Study type
RCTs
Follow-up
Short-Term (≤3 mo)
Risk of bias
Some Concerns
Save research, organize studies, and quickly find important evidence again.
Plain-language summary
A plain-language read of the study’s main message and where it applies.
Study focus
This study evaluated the effects of semaglutide on glycemic control in adults with Type 1 diabetes using automated insulin delivery. Semaglutide improved the percentage of time spent in the target glucose range significantly.
Improving glycemic control is crucial for individuals with Type 1 diabetes, as it can reduce the risk of long-term complications. The significant increase in time spent in the target glucose range with semaglutide suggests it could be a valuable addition to diabetes management strategies, potentially enhancing quality of life and reducing diabetes-related health risks.
The study's sample size and diversity were not specified. The long-term effects of semaglutide were not assessed. Results may not be generalizable to all populations with Type 1 diabetes.
Published in
Publication details and source links for this paper.
Melissa-Rosina P, Michael AT, Alessandra K, Wedyan A, Adnan J, Ahmad H. Semaglutide Improves Glycemic Control with Automated Insulin Delivery in Adults with Type 1 Diabetes. Nature Medicine. 2025;31(4):1239-1245. doi:10.1038/s41591-024-03463-z
Semaglutide increased time in the target glucose range by a mean of 4.8 percentage points (P = 0.006).
No significant difference in percentage of time spent in target glucose range between groups (P = 0.19).
No increase in time spent below 3.9 mmol/l (P = 0.19).
Evidence network
Understand where this research contributes within the broader evidence network.
This study contributes evidence to Semaglutide and Episodes of recurrent euglycemic ketosis without acidosis, Percentage of time spent with sensor glucose levels <3.9 mmol/L, Time in range, and 1 more.
This study contributes evidence to
Primary intervention
Semaglutide
Primary outcomes
Evidence topics
Primary intervention
Intervention and outcome relationships this study adds to the evidence network.
Editorial context
See why this paper is useful beyond its individual results.
Evidence network role
This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.
2
Related topics
4
Evidence pairs
221
Related studies
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Save studies and evidence pages, organize your personal Evidence Tracker, and keep the research you care about in one place.
Primary evidence
Evidence relationship
Related evidence
Evidence topic
Save evidence
Evidence topic
Save evidence
Core evidence
The primary outcomes reported in this study.
Semaglutide → Episodes of recurrent euglycemic ketosis without acidosis
Semaglutide → Episodes of recurrent euglycemic ketosis without acidosis
Semaglutide → Percentage of time spent with sensor glucose levels <3.9 mmol/L
Semaglutide → Percentage of time spent with sensor glucose levels <3.9 mmol/L
Semaglutide → Time spent below 3.0 mmol/L
Semaglutide → Time spent below 3.0 mmol/L
Evidence Library
Save research, organize studies, and quickly find important evidence again.
Evidence Library
Save research, organize studies, and quickly find important evidence again.
Explore related studies, evidence collections, and research questions.
Relationships organized using the Dediabetes Evidence Intelligence™ framework.
This study contributes to evidence on GLP-1 Receptor Agonists and CGM Time in Range, GLP-1 Receptor Agonists and Episodes of recurrent euglycemic ketosis without acidosis.
This study contributes to the evidence on the following intervention-outcome relationships.
Medications
Curated evidence collections and hubs this study is part of.
All studies measuring CGM Time in Range
Measures CGM Time in Range as a key outcome.
All studies on GLP-1 Receptor Agonists
Contributes to GLP-1 Receptor Agonists evidence base.
All studies measuring Episodes of recurrent euglycemic ketosis without acidosis
Measures Episodes of recurrent euglycemic ketosis without acidosis as a key outcome.
Latest published studies
Published within the last 2 years.
Jump to pre-filtered views in Evidence Explorer.
2 results
1 results
2 results
2 results
1 results
Generated from the study's connected evidence using Evidence Intelligence™.
GLP-1 Receptor Agonists may improve CGM Time in Range.
ConsistencyScore™: Results are mixed and should be interpreted cautiously.
Ranked evidence signals
Time in range
EvidenceScore™ Moderate | EvidenceScore™ 69.0 | moderate positive | ConsistencyScore™ Consistent | 1 study
Why this answer: This answer is cautious because the available studies report mixed findings.
Limitations
Current evidence does not show a clear benefit of Semaglutide for Episodes of recurrent euglycemic ketosis without acidosis.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
Episodes of recurrent euglycemic ketosis without acidosis
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | neutral | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Current evidence does not show a clear benefit of Semaglutide for Percentage of time spent with sensor glucose levels <3.9 mmol/L.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
Percentage of time spent with sensor glucose levels <3.9 mmol/L
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | neutral | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Current evidence does not show a clear benefit of Semaglutide for Time spent below 3.0 mmol/L.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
Time spent below 3.0 mmol/L
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | neutral | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Next steps
Choose a next path through related evidence topics, Evidence Explorer views, and research summaries.
Follow the topics this study contributes to.
Open broader Evidence Explorer views for this relationship.
Read related research summaries.
Focused on evidence, not advertising.
Your data is always protected.
New studies added every day.
